Date: 2012-02-02

Type of information: Licensing agreement

Compound: Asparec® (L-asparaginase product)

Company: Alizé Pharma (France) EUSA Pharma, a division of Jazz Pharmaceuticals (Ireland)

Therapeutic area: Cancer - Oncology

Type agreement:


Action mechanism:

Asparec® is Alizé Pharma’s PEGylated recombinant L-asparaginase derived from Erwinia chrysanthemi. It is being developed as a treatment for acute lymphoblastic leukemia (ALL) in patients with hypersensitivity to E. coli-derived L-asparaginase. Preclinical data indicate that ASPAREC is both longer acting and less immunogenic than the currently available Erwinia chrysanthemi derived L-asparaginase product.

Disease: acute lymphoblastic leukemia


Alizé Pharma II, a drug development company focused on oncology and metabolism and part of the Alizé Pharma group, has concluded a licensing agreement with EUSA Pharma for Asparec®, a new L-asparaginase product currently in Phase I clinical development for the treatment of acute lymphoblastic leukemia.

Financial terms:

Pursuant to the agreement, EUSA Pharma will be responsible for the development and worldwide commercialization of Asparec®. In return, Alizé Pharma has received an upfront payment, and will be entitled to additional regulatory milestone payments and royalties on sales. The companies have not disclosed further financial information.

Latest news:

Is general: Yes